SGX Pharmaceuticals Schedules Teleconference and Webcast to Discuss First Quarter 2008 Results and Provide Pipeline Update
06 Mayo 2008 - 3:19PM
PR Newswire (US)
SAN DIEGO, May 6 /PRNewswire-FirstCall/ -- SGX Pharmaceuticals
(NASDAQ:SGXP) will announce financial results for the first quarter
of 2008 on Tuesday May 13, 2008. The announcement will be followed
by a live conference call and webcast at 8:00 a.m. Pacific Time on
that same day. Mike Grey, President and Chief Executive Officer,
Stephen Burley, Chief Scientific Officer and Todd Myers, Chief
Financial Officer, will host the conference call to discuss
financial results and business highlights. A scientific
backgrounder is available at
http://www.sgxpharma.com/pipeline/posterspubs.php Interested
participants and investors may access the teleconference call by
dialing 866-825-1709 (U.S./Canada) or 617-213-8060 (international),
participant code 72662683. A telephonic replay will be available
for seven days following the call. Access numbers for this replay
are 888-286-8010 (U.S./Canada) and 617-801-6888 (international),
participant code 83759897. A live webcast will be available under
the investor relations section of the Company's website at
http://www.sgxpharma.com/. Replays of the webcast will be available
for 30 days following the event. Please connect to the Company's
website several minutes prior to the start of the broadcast to
ensure adequate time for any software download that may be
necessary. About SGX Pharmaceuticals SGX Pharmaceuticals, Inc. is a
biotechnology company focused on the discovery, development and
commercialization of novel, targeted therapeutics directed at
addressing unmet medical needs in oncology. Our drug development
programs target the MET receptor tyrosine kinase, an enzyme
implicated in a broad array of cancers, and the BCR-ABL tyrosine
kinase enzyme for the treatment of Chronic Myelogenous Leukemia, or
CML. Our drug discovery activities are focused on a portfolio of
other protein and enzyme targets that have been implicated in human
cancers including JAK2, RON, ALK, RAS and IKK. More information on
the pipeline and drug discovery platform can be found at
http://www.sgxpharma.com/ and in the Company's various filings with
the Securities and Exchange Commission. DATASOURCE: SGX
Pharmaceuticals CONTACT: Bonnie Feldman, Sr. Director, Investor
Relations of SGX Pharmaceuticals, +1-858-344-8860 Web site:
http://www.sgxpharma.com/
Copyright
Sgx Pharmaceuticals (MM) (NASDAQ:SGXP)
Gráfica de Acción Histórica
De May 2024 a Jun 2024
Sgx Pharmaceuticals (MM) (NASDAQ:SGXP)
Gráfica de Acción Histórica
De Jun 2023 a Jun 2024
Real-Time news about Sgx Pharmaceuticals (MM) (NASDAQ): 0 recent articles
Más de Sgx Pharmaceuticals (MM) Artículos de Noticias